Abstract
The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.
Original language | English (US) |
---|---|
Pages (from-to) | 97S-99S |
Journal | Seminars in cutaneous medicine and surgery |
Volume | 35 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- Atopic dermatitis
- Petrolatum
- Pimecrolimus
- Tacrolimus
- Topical calcineurin inhibitors
- Topical immunomodulators
ASJC Scopus subject areas
- Surgery
- Dermatology